Matthew Baggott is a PhD neuroscientist and data scientists that has published various papers about psychedelics and is the CEO of Tactogen.
Matthew got his PhD at UC Berkeley where he applied machine learning and natural language processing to psychopharmacology. He was also a postdoctoral fellow at the University of Chicago.
Before founding Tactogen in December 2019, he worked at Genentech, Hampton Creek, and Martini Media.
He is also an advisor to the psychedelic venture fund Noetic (Fund II).
Notable Research Papers
- Use patterns and self-reported effects of Salvia divinorum: an internet-based survey (Baggott et al., 2010)
- Subjective and hormonal effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans (Harris et al., 2002)
- Cardiovascular effects of 3, 4-methylenedioxymethamphetamine: a double-blind, placebo-controlled trial (Lester et al., 2000)
- Chemical analysis of ecstasy pills (Baggott et al., 2000)
- Seed crystal: on the contributions of Alexander Shulgin to the science of consciousness (Medium, June 2020)
- Psychedelics in American Religious Experience (Medium, April 2015)